Which is the most effective weight loss injection available in the UK?

The misconception: one injection is simply 'stronger' than the other

Most searches on this topic expect a clean ranking, as if one pen is categorically better and the other a consolation prize. That framing misses something important. Both tirzepatide and semaglutide work by reducing appetite and slowing the rate at which food leaves the stomach, but they do so through different mechanisms. Semaglutide activates the GLP-1 receptor; tirzepatide activates both GLP-1 and GIP receptors, making it the only dual-agonist weight-loss medicine licensed in the UK. The dual action appears to drive greater average results across large trial populations, but averages describe groups, not individuals. Some people on semaglutide lose more weight than others on tirzepatide, biology, adherence, diet and activity all play a role the trials can't fully separate out.

The other thing worth correcting: 'most effective' is often read as 'most tolerable', and the two don't always align. A medicine that produces 22% average weight loss but causes persistent nausea that someone can't manage is not the most effective option for them. Our clinical team makes this judgment individually, which is why a prescriber reviews every consultation rather than an automated system.

What the trial data actually says

The clearest comparison comes from SURMOUNT-5, a head-to-head trial published in the New England Journal of Medicine in 2025, involving 751 adults with obesity and no diabetes over 72 weeks. Tirzepatide produced greater average weight reduction than semaglutide 2.4 mg, a meaningful difference, though both arms lost substantial weight. SURMOUNT-1 (tirzepatide alone, 2,539 participants) reported around 20–21% average body-weight reduction at the 15 mg dose. The STEP 1 trial established semaglutide 2.4 mg at roughly 15% average weight loss over 68 weeks, as detailed in the same journal.

The picture shifted again in early 2026. The MHRA approved a dedicated 7.2 mg Wegovy pen in April 2026, with trials reporting around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide considerably. NICE's appraisal of tirzepatide (TA1026) and its earlier recommendation for semaglutide (TA875) both note that indirect comparisons favour tirzepatide, while acknowledging the evidence base continues to grow. So the honest answer is: tirzepatide leads on average results, but not by the margin people often assume, and if you want a deeper look at what's the most effective weight loss injection given where the evidence now sits, the 7.2 mg semaglutide option has genuinely changed the landscape.

Eligibility shapes the 'best' answer more than the trial averages do

Both injections are licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. But licensed doesn't mean automatically suitable. A person with a history of pancreatitis, certain gastrointestinal conditions or specific thyroid conditions requires a careful prescriber assessment before either medicine is considered. Other medicines already being taken (particularly oral contraceptives, where tirzepatide can reduce absorption during the first four weeks of each dose increase) are factored in too.

There's also the practical question of form. Wegovy is now available as a once-daily tablet (approved by the MHRA in June 2026), which changes the picture for people who are anxious about injections. If that's relevant to you, comparing the injection and tablet options is a sensible starting point. Understanding how effective weight-loss injections are in practice (beyond the headline trial figures) also helps set realistic expectations before committing to treatment.

What a clinical assessment changes

A prescriber looking at your consultation isn't just verifying a BMI number. They're weighing up your full health picture, your previous attempts, any medicines you already take, and which of the available options is most likely to work safely and sustainably for you. That's the assessment that turns a trial average into a personalised decision.

For context on the cost of treatment, the treatment and pricing page sets out what's included. These are prescription medicines, so the prescription and clinical review are part of the price, not extras bolted on. A good rule of thumb: if a price looks suspiciously low, it's worth asking what's been left out. The NHS warns about counterfeit pens sold without a prescription via social media, the MHRA's Yellow Card scheme is the right place to report anything suspicious.

If you're weighing up your options and want to understand how weight-loss injections work in practice, or you'd like a clearer sense of which treatment is likely to suit you before speaking to a prescriber, our page on the most effective weight loss injection is a good place to read up first. Our prescribers review every application the same day (a named clinician reads your answers, not software) and if treatment is clinically appropriate, it's dispatched the same day you're approved. Start your free consultation whenever you're ready.